PURPOSE: Extended-release (ER) monthly injectable buprenorphine offers an alternative to daily sublingual (SL) dosing for treatment of opioid use disorder (OUD) that may be attractive to several patient populations, including those with barriers to adherence and the frequent follow-up that are necessary for traditional SL buprenorphine. Despite the potential benefits of ER-buprenorphine, there are significant barriers to healthcare provider adoption that may prevent utilization in the populations that would benefit. SUMMARY: Our health system began providing clinic-administered ER-buprenorphine as treatment for OUD in May 2018 at a single clinic. Expansion was limited due to difficulties with delayed and inaccurate medication delivery and heavy administrative burden. To facilitate uptake of ER-buprenorphine for patients who could benefit, our integrated health-system specialty pharmacy (HSSP) assumed responsibility for medication distribution and administrative management beginning in October 2019. The HSSP provided accurate medication delivery, alleviated administrative burdens of benefits investigation and Risk Evaluation and Mitigation Strategy compliance, and decreased medication wastage by implementing a medication return process. Subsequently, ER-buprenorphine services were expanded to 4 additional sites, allowing 244 more patients to receive treatment. CONCLUSION: HSSP support can provide significant benefit to patients and the health system through coordinating ER-buprenorphine dispensing and delivery.
|Journal||Bulletin. American Society of Hospital Pharmacists|
|State||Published - Jan 1 2023|
Bibliographical notePublisher Copyright:
Published by Oxford University Press on behalf of the American Society of Health-System Pharmacists 2022.
- health-system specialty pharmacy
- opioid use disorder
ASJC Scopus subject areas
- Health Policy